Many pharma companies are developing inhaled antibiotics for patients with bronchiectasis, recognizing the increasing market (over 110,000 patients in the US). These drugs cost thousands of dollars per year and will be heavily marketed and heavily used, as there are limited options for these patients. It is unknown if rotating oral antibiotics (cost is a fraction of the inhaled ABx) would yield similar results. A Cochrane analysis of chronic antibiotics in bronchiectasis suggested benefit, but there were very few studies. A comparative effectiveness study would be of benefit. No studies of this question are ongoing to my knowledge.